Definitive Healthcare (NASDAQ:DH - Get Free Report) is expected to be announcing its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $56.20 million for the quarter. Definitive Healthcare has set its FY 2025 guidance at 0.190-0.220 EPS and its Q1 2025 guidance at 0.020-0.020 EPS.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to analysts' expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. On average, analysts expect Definitive Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Definitive Healthcare Trading Down 3.4 %
Shares of DH traded down $0.10 during trading hours on Tuesday, hitting $2.68. The stock had a trading volume of 390,511 shares, compared to its average volume of 854,678. Definitive Healthcare has a 12-month low of $2.15 and a 12-month high of $7.47. The firm has a market cap of $288.80 million, a P/E ratio of -0.86, a P/E/G ratio of 4.06 and a beta of 1.48. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The company's fifty day simple moving average is $2.70 and its 200 day simple moving average is $3.90.
Analyst Upgrades and Downgrades
DH has been the topic of several research analyst reports. Barclays reduced their price objective on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research note on Monday, March 3rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, The Goldman Sachs Group dropped their price objective on shares of Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Definitive Healthcare currently has a consensus rating of "Hold" and an average price target of $5.35.
Check Out Our Latest Report on Definitive Healthcare
About Definitive Healthcare
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
See Also
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
